JPMORGAN CHASE & CO - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 163 filers reported holding ALLOGENE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.5%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$21,907,495
-28.1%
6,910,882
+12.7%
0.00%
-33.3%
Q2 2023$30,487,943
+22.8%
6,134,395
+22.1%
0.00%0.0%
Q1 2023$24,821,000
+104563.7%
5,024,544
+33.3%
0.00%0.0%
Q4 2022$23,715
-99.9%
3,770,283
-4.9%
0.00%
-50.0%
Q3 2022$42,830,000
-16.6%
3,965,620
-11.9%
0.01%
-14.3%
Q2 2022$51,335,000
+58.4%
4,502,994
+26.6%
0.01%
+75.0%
Q1 2022$32,406,000
-40.1%
3,557,117
-1.8%
0.00%
-33.3%
Q4 2021$54,059,000
-36.7%
3,623,279
+9.1%
0.01%
-45.5%
Q3 2021$85,370,000
+31.7%
3,321,800
+33.7%
0.01%
+37.5%
Q2 2021$64,802,000
-22.9%
2,484,735
+4.3%
0.01%
-27.3%
Q1 2021$84,080,000
+70.2%
2,381,867
+21.7%
0.01%
+57.1%
Q4 2020$49,397,000
-22.4%
1,957,089
+15.9%
0.01%
-36.4%
Q3 2020$63,669,000
+5.4%
1,687,916
+19.7%
0.01%
-8.3%
Q2 2020$60,395,000
+700.8%
1,410,446
+263.5%
0.01%
+500.0%
Q1 2020$7,542,000
+244.7%
387,984
+360.6%
0.00%
Q4 2019$2,188,000
+528.7%
84,237
+560.3%
0.00%
Q3 2019$348,000
+22.1%
12,758
+19.3%
0.00%
Q2 2019$285,000
+82.7%
10,695
+98.3%
0.00%
Q1 2019$156,000
+5.4%
5,392
-2.0%
0.00%
Q4 2018$148,0005,5040.00%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
Vida Ventures Advisors, LLC 1,798,163$46,213,00013.24%
Wildcat Capital Management, LLC 1,716,370$44,111,0005.71%
TPG Group Holdings (SBS) Advisors, Inc. 18,716,306$481,009,0004.77%
Copernicus Capital Management, LLC 15,000$386,0004.67%
Coastal Bridge Advisors, LLC 301,240$7,742,0001.79%
Lombard Odier Asset Management (Switzerland) SA 914,416$23,500,0001.46%
Casdin Capital, LLC 2,100,000$53,970,0001.34%
Pier Capital, LLC 450,182$11,570,0001.20%
Ghost Tree Capital, LLC 150,000$3,855,0001.13%
Sessa Capital IM, L.P. 750,000$19,275,0000.95%
View complete list of ALLOGENE THERAPEUTICS INC shareholders